23.8 C
New York
Wednesday, June 10, 2026

Tag: confidence

newssourceFORcompanyinformationcontent1marketreleases

Classico Pokemon Collection: “Stay with Your Favorite Pokemon Everywhere”

TOKYO, June 8, 2026 /PRNewswire/ -- Classico, Inc., a Japanese medical apparel brand headquartered in Tokyo, launched the highly anticipated #ClassicoPokemonCollection across the Asian...

TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging

TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...

New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales

Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...

Finnate Listed on PathFin.ai Knowledge Hub under the MAS Pathfinder Programme Following Independent Review and Verification Process

MAS Pathfinder Programme listing reflects Finnate's governance-focused design and real-world deployment maturity across regulated financial servicesMELBOURNE, Australia, June 8, 2026 /PRNewswire/ -- Centelon announced that...

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

Enabled Talent launches One Company. One Talent, inviting Canadian employers to create one inclusive opportunity and build a stronger workforce.

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance 

University of Phoenix researchers publish study examining doctoral students’ attitudes toward AI chatbots and ChatGPT use in higher education

Peer-reviewed study by Center for Educational and Instructional Technology Research team highlights connections between student perceptions of AI, academic integrity concerns and reported chatbot...

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P...

BIRKS GROUP ANNOUNCES THE CLOSING OF A NEW TERM LOAN FACILITY WITH GORDON BROTHERS REPLACING ITS FORMER TERM LOAN FACILITY AND THE EXTENSION OF...

All figures presented herein are in Canadian dollars, unless indicated otherwise.MONTREAL, June 5, 2026 /CNW/ - Birks Group Inc. ("Birks Group" or the "Company")...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsConfidence

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers